Data from University of Texas MD Anderson Cancer Center Provide New Insights into Antibodies (Preclinical Development of 1b7/cd3, a Novel Anti-tslpr Bispecific Antibody That Targets Crlf2-rearranged Ph-like B-all).

MLA

“Data from University of Texas MD Anderson Cancer Center Provide New Insights into Antibodies (Preclinical Development of 1b7/Cd3, a Novel Anti-Tslpr Bispecific Antibody That Targets Crlf2-Rearranged Ph-like B-All).” Health & Medicine Week, Oct. 2023, p. 1502. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=172943492&authtype=sso&custid=ns315887.

APA

Data from University of Texas MD Anderson Cancer Center Provide New Insights into Antibodies (Preclinical Development of 1b7/cd3, a Novel Anti-tslpr Bispecific Antibody That Targets Crlf2-rearranged Ph-like B-all). (2023). Health & Medicine Week, 1502.

Chicago

“Data from University of Texas MD Anderson Cancer Center Provide New Insights into Antibodies (Preclinical Development of 1b7/Cd3, a Novel Anti-Tslpr Bispecific Antibody That Targets Crlf2-Rearranged Ph-like B-All).” 2023. Health & Medicine Week, October, 1502. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=172943492&authtype=sso&custid=ns315887.